Latest Health Care News

Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.

WAM Leaders Limited reported a strong $63.8 million net profit for FY2025 and declared a fully franked final dividend of 4.7 cents per share, despite its investment portfolio underperforming the benchmark index.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Australian Foundation Investment Company Limited (AFIC) reported a $285 million net profit for FY2025, declaring a fully franked 14.5c final dividend plus a 5c special dividend tied to capital gains from portfolio adjustments.

Mirrabooka Investments reports a 26% drop in net profit for FY25 but maintains its fully franked dividend, supported by a significant $85 million capital raise. The fund’s portfolio return lags the benchmark amid sector headwinds, yet long-term performance remains robust.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Emyria reports sustained six-month improvements in treatment-resistant PTSD patients and announces a strategic research collaboration with Australian National University to advance mental health care models.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed a significant five-year, A$20 million contract to implement its cloud-based Visage 7 imaging platform at University of Iowa Health Care, marking a major step in cloud adoption for healthcare IT.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.